Prognostic significance of EZH2 expression in non-small cell lung cancer: A meta-analysis

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Wang, Xinhua ^a   Zhao, Hongqing ^a   Lv, Lei ^a   Bao, Liang ^a   Wang, Xun ^a   Han, Shuguang ^a  

^a WUXI NO 2 PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EZH2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR EZH2;

ASIAN CONTINENTAL ANCESTRY GROUP; CANCER GRADING; CANCER STAGING; CAUCASIAN; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG TUMOR; META ANALYSIS; MORTALITY; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROGNOSIS; PUBLISHING;

ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PUBLICATION BIAS;

EID: 84954430798     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep19239     Document Type: Article

References (31)

1. Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer statistics, 2014. CA Cancer J Clin. 64, 9-29 (2014
2. Molina, J. R. et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 83, 584-594 (2008
3. Alberg, A., Ford, J. & Samet, J. Epidemiology of Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines. Chest. 132, 29-55S (2007
4. Paesmans, M. et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1, 052 patients. The European Lung Cancer Working Party. J Clin Oncol. 13, 1221-1230 (1995
5. Donnem, T., Bremnes, R. M., Busund, L. T., Andersen, S. & Pezzella, F. Gene expression assays as prognostic and predictive markers in early stage non-small cell lung cancer. J Thorac Dis. 4, 212-213 (2012
6. Margueron, R. & Reinberg, D. The polycomb complex PRC2 and its mark in life. Nature. 469, 343-9 (2011
7. Kleer, C. G. et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA. 100, 11606-11 (2003
8. Varambally, S. et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 419, 624-9 (2002
9. Matsukawa, Y. et al. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci. 97, 484-91 (2006
10. Wang, C. G. et al. EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis. World J Gastroenterol. 16, 2421-7 (2010
11. Lu, C. et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell. 18, 185-97 (2010
12. Altman, D. G. Systematic reviews of evaluations of prognostic variables. BMJ. 323, 224-228 (2001
13. Parmar, M. K., Torri, V. & Stewart, L. Extracting summary statistics to perform metaanalyses of the published literature for survival endpoints. Stat Med. 17, 2815-2834 (1998
14. Yusuf, S. et al. Blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 27, 335-371 (1985
15. DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Controlled Clinical Trials. 7, 177-188 (1986
16. Egger, M., Smith, G. D. & Schneider, M. Bias in meta-analysis detected by a simple, graphical test. BMJ. 315, 629-634 (1997
17. Begg, C. B. & Mazumdar, M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 50, 1088-1101 (1994
18. Behrens, C. et al. EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma. Clin Cancer Res. 19, 6556-65 (2013
19. Zhang, J. L. et al. Expression of EZH2 in non-small cell lung cancer and its clinical signification. J of inner Mongolia med univ. 35, 12-16 (2013).[in Chinese].
20. Chen, X. et al. High expression of trimethylated histone H3 at lysine 27 predicts better prognosis in non-small cell lung cancer. Int J Oncol. 43, 1467-80 (2013
21. Huqun. et al. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer. Cancer. 118, 1599-606 (2012
22. Takawa, M. et al. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci. 102, 1298-305 (2011
23. Kikuchi, J. et al. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance. Cancer. 116, 3015-24 (2010
24. Xu, C. et al. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy. Lung Cancer. 86, 268-73 (2014
25. Riquelme, E. et al. VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy. Clin Cancer Res. 20, 3849-61 (2014
26. Cao, W. et al. EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer. PLoS One. 7, e52984 (2012
27. Yu, J. et al. Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell. 12, 419-31 (2007
28. Cao, Q. et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene. 27, 7274-84 (2008
29. Varambally, S. et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 419, 624-9 (2002
30. Guo L., Yang T. F., Liang S. C., Guo J. X. & Wang G. Q. Role of EZH2 protein expression in gastric carcinogenesis among Asians: a meta-analysis. Tumor Biol. 35, 6649-6656 (2014
31. Begg, C. B. & Berlin, J. A. Publication bias: A problem in interpreting medical data. J R Stat Soc A. 151, 419-463 (1988